Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease

被引:64
作者
Robbins, EM
Betensky, RA
Domnitz, SB
Purcell, SM
Garcia-Alloza, M
Greenberg, C
Rebeck, GW
Hyman, BT
Greenberg, SM
Frosch, MP
Bacskai, BJ
机构
[1] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Alzheimer Res Unit, Charlestown, MA 02129 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[3] Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA
[4] Massachusetts Gen Hosp, Dept Pathol, CS Kubik Lab Neuropathol, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
amyloid-beta; Alzheimer; vascular; angiopathy; mouse; transgenic;
D O I
10.1523/JNEUROSCI.3854-05.2006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cerebral amyloid angiopathy (CAA), the deposition of cerebrovascular beta-amyloid (A beta) in the walls of arterial vessels, has been implicated in hemorrhagic stroke and is present in most cases of Alzheimer disease. Previous studies of the progression of CAA in humans and animal models have been limited to the comparison of pathological tissue from different brains at single time points. Our objective was to visualize in real time the initiation and progression of CAA in Tg2576 mice by multiphoton microscopy through cranial windows. Affected vessels were labeled by methoxy-X04, a fluorescent dye that selectively binds cerebrovascular beta-amyloid and plaques. With serial imaging sessions spaced at weekly intervals, we were able to observe the earliest appearance of CAA in leptomeningeal arteries as multifocal deposits of band-like A beta. Over subsequent imaging sessions, we were able to identify growth of these deposits ( propagation), as well as appearance of new bands ( additional initiation events). Statistical modeling of the data suggested that as the extent of CAA progressed in this vascular bed, there was increased prevalence of propagation over initiation. During the early phases of CAA development, the overall pathology burden progressed at a rate of 0.35% of total available vessel area per day (95% confidence interval, 0.3 - 0.4%). The consistent rate of disease progression implies that this model is amenable to investigations of therapeutic interventions.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 43 条
[1]   Progression of cerebral amyloid angiopathy:: Accumulation of amyloid-β40 in affected vessels [J].
Alonzo, NC ;
Hyman, BT ;
Rebeck, GW ;
Greenberg, SM .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (04) :353-359
[2]   Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy [J].
Backskai, BJ ;
Kajdasz, ST ;
Christie, RH ;
Carter, C ;
Games, D ;
Seubert, P ;
Schenk, D ;
Hyman, BT .
NATURE MEDICINE, 2001, 7 (03) :369-372
[3]   Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies [J].
Cadavid, D ;
Mena, E ;
Koeller, K ;
Frommelt, RA .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (09) :768-773
[4]   Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid [J].
Calhoun, ME ;
Burgermeister, P ;
Phinney, AL ;
Stalder, M ;
Tolnay, M ;
Wiederhold, KH ;
Abramowski, D ;
Sturchler-Pierrat, C ;
Sommer, B ;
Staufenbiel, M ;
Jucker, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :14088-14093
[5]   Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy [J].
Christie, R ;
Yamada, M ;
Moskowitz, M ;
Hyman, B .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (03) :1065-1071
[6]   Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy [J].
Christie, RH ;
Bacskai, BJ ;
Zipfel, WR ;
Williams, RM ;
Kajdasz, ST ;
Webb, WW ;
Hyman, BT .
JOURNAL OF NEUROSCIENCE, 2001, 21 (03) :858-864
[7]   Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease [J].
Domnitz, SB ;
Robbins, EM ;
Hoang, AW ;
Garcia-Alloza, M ;
Hyman, BT ;
Rebeck, GW ;
Greenberg, SM ;
Bacskai, BJ ;
Frosch, MP .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (07) :588-594
[8]  
Fryer JD, 2003, J NEUROSCI, V23, P7889
[9]   ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN [J].
GAMES, D ;
ADAMS, D ;
ALESSANDRINI, R ;
BARBOUR, R ;
BERTHELETTE, P ;
BLACKWELL, C ;
CARR, T ;
CLEMENS, J ;
DONALDSON, T ;
GILLESPIE, F ;
GUIDO, T ;
HAGOPIAN, S ;
JOHNSONWOOD, K ;
KHAN, K ;
LEE, M ;
LEIBOWITZ, P ;
LIEBERBURG, I ;
LITTLE, S ;
MASLIAH, E ;
MCCONLOGUE, L ;
MONTOYAZAVALA, M ;
MUCKE, L ;
PAGANINI, L ;
PENNIMAN, E ;
POWER, M ;
SCHENK, D ;
SEUBERT, P ;
SNYDER, B ;
SORIANO, F ;
TAN, H ;
VITALE, J ;
WADSWORTH, S ;
WOLOZIN, B ;
ZHAO, J .
NATURE, 1995, 373 (6514) :523-527
[10]   Amyloid angiopathy-related vascular cognitive impairment [J].
Greenberg, SA ;
Gurol, ME ;
Rosand, J ;
Smith, EE .
STROKE, 2004, 35 (11) :2616-2619